Top-Rated StocksTop-RatedNASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis $33.13 +0.83 (+2.57%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$32.48 -0.65 (-1.95%) As of 06/9/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Cytokinetics Stock (NASDAQ:CYTK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cytokinetics alerts:Sign Up Key Stats Today's Range$32.30▼$33.2950-Day Range$29.84▼$42.9252-Week Range$29.31▼$61.38Volume1.36 million shsAverage Volume1.55 million shsMarket Capitalization$3.96 billionP/E RatioN/ADividend YieldN/APrice Target$70.92Consensus RatingModerate Buy Company OverviewCytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More… Cytokinetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreCYTK MarketRank™: Cytokinetics scored higher than 81% of companies evaluated by MarketBeat, and ranked 329th out of 1,886 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cytokinetics are expected to decrease in the coming year, from ($5.24) to ($5.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cytokinetics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.36% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Cytokinetics has recently increased by 7.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.83 Percentage of Shares Shorted13.36% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Cytokinetics has recently increased by 7.73%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.60 News SentimentCytokinetics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Cytokinetics this week, compared to 10 articles on an average week.Search Interest5 people have searched for CYTK on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,518,893.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of Cytokinetics is held by insiders.Read more about Cytokinetics' insider trading history. Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Stock News HeadlinesCytokinetics, Incorporated (NASDAQ:CYTK) Director Muna Bhanji Sells 1,454 SharesMay 16, 2025 | insidertrades.comJPMorgan Chase & Co. Has Lowered Expectations for Cytokinetics (NASDAQ:CYTK) Stock PriceJune 10 at 2:22 AM | americanbankingnews.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we've imagined robots doing things like cleaning our homes, serving drinks at restaurants, greeting guests in hotel lobbies, stacking shelves in warehouses, and so on. Very soon, there will be a robot that won't do any of that. However, it's impact on the US economy and society will be FAR greater than anything we ever imagined.June 10, 2025 | Weiss Ratings (Ad)Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK)June 3, 2025 | gurufocus.comCytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by AnalystsJune 1, 2025 | americanbankingnews.comCytokinetics to Participate in the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comStifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)May 29, 2025 | theglobeandmail.comCytokinetics at RBC Conference: Strategic Insights on Drug DevelopmentMay 23, 2025 | uk.investing.comSee More Headlines CYTK Stock Analysis - Frequently Asked Questions How have CYTK shares performed this year? Cytokinetics' stock was trading at $47.04 at the start of the year. Since then, CYTK stock has decreased by 29.6% and is now trading at $33.13. View the best growth stocks for 2025 here. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) announced its earnings results on Tuesday, May, 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, beating the consensus estimate of ($1.41) by $0.05. Cytokinetics's revenue for the quarter was up 89.1% on a year-over-year basis. Read the conference call transcript. Who are Cytokinetics' major shareholders? Top institutional shareholders of Cytokinetics include Vanguard Group Inc. (9.94%), T. Rowe Price Investment Management Inc. (8.34%), Vestal Point Capital LP (2.17%) and Price T Rowe Associates Inc. MD (1.67%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, John T Henderson, Andrew Callos, Edward M Md Kaye, Wendall Wierenga, Muna Bhanji, B Lynne Parshall, Robert Wong and Robert Arthur Harrington. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Adobe (ADBE) and GE Aerospace (GE). Company Calendar Last Earnings5/06/2025Today6/09/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYTK CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees250Year Founded1997Price Target and Rating Average Stock Price Target$70.92 High Stock Price Target$120.00 Low Stock Price Target$41.00 Potential Upside/Downside+114.1%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$526.24 million Net Margins-17,906.25% Pretax Margin-17,906.25% Return on EquityN/A Return on Assets-50.21% Debt Debt-to-Equity Ratio5.93 Current Ratio9.28 Quick Ratio9.28 Sales & Book Value Annual Sales$19.22 million Price / Sales205.88 Cash FlowN/A Price / Cash FlowN/A Book Value($3.94) per share Price / Book-8.41Miscellaneous Outstanding Shares119,427,000Free Float114,002,000Market Cap$3.96 billion OptionableOptionable Beta0.59 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:CYTK) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s treachery A few months ago, I released a list of six companies I believed were going to appreciate under Trump’s second ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredElon’s “Secret Mission”Tesla, SpaceX and Starlink made billions for investors... But a meeting Elon had on March 21st, 2025, could...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.